Emmett12,There is a lot to like here as you mention. The value...

Emmett12,

There is a lot to like here as you mention. The value is in the new acquisition of cynata. Clearly all involved think there is considerable value in monetising this technology.

All I know is the sub 10m market cap in a buoyant sector with good management can do a lot of things.

The thing will be how quickly they can move through the trials. The testing on rats is a huge plus for ECM's and particularly ecq sdhareholders.

Patience may be well rewarded at these basement prices imo